ストックスクリーナーアプリを入手
4.10
9.89%
-0.45
アフターアワーズ：
4.10
Anteris Technologies Global Corp (AVR) 最新ニュース
Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones - Proactive financial news
Anteris scales for pivotal PARADIGM Trial, plunging R&D investment into clinical activities - Proactive financial news
The morning catch up: ASX to extend gains as global optimism lifts markets - Proactive financial news
Anteris Technologies Advances Clinical Trial Efforts with DurAVR® THV - TipRanks
Anteris Technologies Reports Q1 2025 Results and Strategic Fund Allocation - TipRanks
Anteris Announces Results for the First Quarter of 2025 - The Manila Times
Anteris Technologies Files Amendment to Annual Report - TipRanks
Anteris Technologies Announces Cessation of Certain Securities - TipRanks
Anteris Technologies Global Corp. (AVR) Receives a Buy from Lake Street - The Globe and Mail
ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium - businessnews.com.au
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target - Investing.com
Anteris Technologies Announces Cessation of Securities - TipRanks
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve - Proactive financial news
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Anteris Technologies Global (NASDAQ:AVR) Stock Price Down 6.2% – What’s Next? - Defense World
Anteris Technologies: Advancing Toward FDA Approval with Positive Buy Rating - TipRanks
Anteris Technologies reports annual financial results By Investing.com - Investing.com South Africa
Anteris Technologies reports annual financial results - Investing.com India
Anteris Technologies 2024 financials strong following Nasdaq debut, with plans for heart valve pivotal trial this year - Proactive financial news
Anteris Technologies: A Trailblazing Year of Innovation and Expansion - Kondor EXP
The morning catch up: ASX to reverse losses despite war of words over tariffs - Proactive financial news
3.24%
大文字化:
|
ボリューム (24 時間):